About Healius (ASX: HLS)
Healius Limited is an Australian healthcare company focused on the provision of medical laboratory and pathology services across Australia, operating a network of medical laboratories and patient collection centres that serve both clinical and diagnostic needs.
The company delivers its services through a broad portfolio of brands, including Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs. Formerly known as Primary Health Care Limited, the company adopted the Healius name in December 2018. Incorporated in 1994, Healius is headquartered in Sydney, Australia.
MFAM Research
- [BUY] Healius (ASX:HLS) is an Undervalued Healthcare Services Provider in a Growing IndustryOctober 8, 2020Today we’ll look at why we like Healius shares (ASX:HLS) and we’ll give you a rundown of our HLS share price forecast. Healius is a healthcare services provider with three main businesses – pathology, imaging and medical centres. With an aging population and a growing pathology industry, Healius is well-positioned to take advantage of the […]
Latest Announcements
- Healius (ASX: HLS) – Transitions pathology arrangements with Ramsay 3June 26, 2026Healius Limited has secured renewal of its pathology service arrangements with Ramsay Health Care subsidiaries, with the agreement expected to generate approximately $45 million in annual revenue under the initial contract terms. The transition takes effect on 1 July 2026 and consolidates Healius’ existing pathology leases and service arrangements across thirteen Ramsay-operated hospitals into a […]
- Healius (ASX: HLS) – FY26 Trading Update and Strategic ReviewMay 13, 2026Healius Limited has provided a FY26 trading update that reveals a company navigating conflicting pressures. The company expects underlying EBITDA between 259 million and 264 million dollars, with EBIT guidance of 30 million to 35 million dollars. Concurrent with these financial projections, Healius has engaged UBS Securities to explore a sale of Agilex Biolabs, its […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Diagnostics & Research |
|---|---|